Axon Enterprise, Inc. filings document operating results and corporate actions for a public safety technology company with Software & Services and Connected Devices activities. Form 8-K reports include shareholder letters on financial results and outlooks, product demand across TASER devices, Axon Body cameras, Axon Evidence, AI products, counter-drone offerings and real-time operations, as well as material-event disclosures tied to capital structure.
Proxy materials cover board composition, shareholder meeting matters, executive compensation and equity awards. Other 8-K and 8-K/A filings record director election updates and the redemption and settlement of 0.50% convertible senior notes due 2027, including the disclosure that no convertible notes remained outstanding after the redemptions and conversions.
Axon Enterprise, Inc. chief revenue officer Cameron Brooks had 5,850 shares withheld on October 1, 2026, to settle tax liability arising from vesting of the third tranche of restricted stock units granted under the 2024 eXponential Stock Plan. The reported per-share price was $422.21, and his direct holdings following the transaction were 61,396 shares. The Compensation Committee certified the tranche’s performance conditions on November 13, 2025. No Rule 10b5-1 plan is reported.
Axon Enterprise, Inc. (AXON) issued and sold $1.15 billion aggregate principal amount of 0% Convertible Senior Notes due 2031, including $150 million from the underwriters’ over-allotment option, under an Indenture with U.S. Bank Trust Company.
The Notes mature on September 15, 2031, bear no regular interest and have an initial conversion rate of 1.5336 shares per $1,000 principal amount, equivalent to a conversion price of about $652.06 per share, subject to customary adjustments and make-whole increases upon certain events. Axon may redeem the Notes for cash on or after September 20, 2029 if its stock trades at least 130% of the conversion price, and holders have repurchase rights upon a Fundamental Change and on or around March 20, 2031. Axon entered into capped call transactions covering the shares underlying the Notes, with an initial cap price of $1,049.94 per share, paying about $114.9 million to reduce potential dilution and/or excess cash outlays on conversion, and plans to use the remaining net proceeds for general corporate purposes.
Axon Enterprise, Inc. (AXON) is issuing $1.0 billion principal amount of 0% Convertible Senior Notes due 2031, with an additional $150.0 million over‑allotment option. The notes mature on September 15, 2031, bear no regular interest and are convertible into Axon common stock at an initial rate of 1.5336 shares per $1,000 principal (initial conversion price about $652.06 per share), subject to customary anti‑dilution adjustments.
Axon may redeem the notes for cash on or after September 20, 2029 if its stock trades at least 130% of the then‑effective conversion price for a specified period, and may also execute a “cleanup” redemption if less than 10% of the original principal remains outstanding. Holders receive put protection via a fundamental change repurchase right and a separate optional repurchase right around March 20, 2031. The notes are senior unsecured obligations, ranking equally with Axon’s other unsubordinated debt (including its 2030 and 2033 senior notes), effectively junior to secured debt and structurally junior to subsidiary liabilities. Concurrently, Axon is amending its credit agreement to expand its revolving facility from $300.0 million to $500.0 million with an additional $150.0 million accordion and to extend the facility’s maturity, conditioned on completion of this offering.
Axon Enterprise, Inc. (AXON) is offering $1,000,000,000 principal amount of 0% Convertible Senior Notes due 2031 under its shelf registration. The notes pay no regular interest, mature on September 15, 2031, and are convertible into cash, common stock, or a combination at Axon’s election, subject to stock-price and trading-condition triggers before June 15, 2031 and freely thereafter.
Axon may redeem the notes for cash starting September 20, 2029 if its share price is at least 130% of the conversion price for a specified period, and may execute a “cleanup redemption” once less than 10% of the original principal remains outstanding. Holders can require cash repurchase after certain fundamental changes and have an additional put right around March 20, 2031.
The notes rank as senior unsecured obligations, equal to other unsecured debt and effectively junior to secured and subsidiary liabilities. Concurrently, Axon amended its credit agreement to increase its revolving facility from $300 million to $500 million (with a further $150 million upsizing option) and extend its maturity subject to conditions tied to these notes. In 2025 Axon generated about $2.78 billion in net sales and $124.7 million in net income, and reports a total addressable market of $159 billion with roughly 75% of revenue from U.S. state and local law enforcement.
Axon Enterprise, Inc. (AXON) entered into a Second Amendment to its Credit Agreement, conditioned upon consummation of an offering of 0% Convertible Notes due 2031. The amendment is expected to increase the revolving credit facility from $300.0 million to $500.0 million with the ability to increase it by an additional $150.0 million, and to extend the maturity to up to five years from the closing of the Second Amendment, subject to detailed conditions linked to Axon’s convertible and other permitted convertible indebtedness.
The Revolving Facility will bear interest at SOFR plus 1.25% to 1.75% per year, with a 0.15% per annum commitment fee on unused commitments, and continues to include financial and operational covenants, including a maximum net leverage ratio of 3.50 to 1.00 (with a temporary 1.00 step-up after certain acquisitions) and a minimum interest coverage ratio of 3.50 to 1.00. Axon separately announced a proposed public offering of $1.0 billion aggregate principal amount of 0% convertible senior notes due 2031, with an expected $150.0 million over-allotment option, and plans to use part of the net proceeds to fund capped call transactions and the remainder for general corporate purposes, including potential acquisitions and growth investments.
Axon Enterprise, Inc. (AXON) reported that Chief Legal Officer Isaiah Fields sold common stock in a routine insider transaction. On September 11, 2026, he sold 1,017 shares at a price of $480.45 per share in an open-market or private sale. After this sale, he beneficially owned 56,263.855 shares of Axon common stock directly. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on June 12, 2026.
Axon Enterprise, Inc. officer Isaiah Fields filed a notice of proposed sale of 1,017 shares of common stock under Rule 144. The shares are to be sold through Morgan Stanley Smith Barney LLC, with an aggregate market value of $486,990.45, based on Axon’s reported 81,237,415 shares outstanding and a proposed sale date of September 11, 2026 on NASDAQ.
AXON ENTERPRISE, INC. (AXON) reported that Chief Executive Officer and director Patrick W. Smith sold a total of 10,000 shares of common stock on September 8, 2026. The sales were executed in multiple trades at weighted average prices ranging from $501.99 to $513.38 per share under a Rule 10b5-1 trading plan adopted on May 12, 2025.
AXON ENTERPRISE, INC. (AXON) is the issuer for a Rule 144 notice filed for the account of Patrick W. Smith, covering a proposed sale of 10,000 shares of Axon common stock through UBS Financial Services Inc. The shares relate to an option exercise on November 15, 2021, to be sold for cash. As of September 8, 2026, Axon had 81,237,415 common shares outstanding; this is a baseline figure, not the amount being offered. The notice also lists prior sales by Smith over the past three months, each for 10,000 shares of common stock.
AXON ENTERPRISE, INC. (AXON) reported that Chief Accounting Officer Jennifer H. Mak had 155.674 shares of common stock withheld on August 31, 2026 to pay tax liability arising from the vesting of restricted stock units, at a reference price of $566.56 per share. After this tax-withholding disposition, she directly holds 13,600.294 shares of Axon common stock, and no Rule 10b5-1 trading plan is reported.